The Association of Opioid Use, Sleep-Disordered Breathing, and Mortality in the DREAM Study

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 959A
Author(s):  
Husham Sharifi ◽  
Megan Sands ◽  
Selim Bernardo ◽  
Kingman Strohl ◽  
Jared Ferguson ◽  
...  
2020 ◽  
Vol 37 (11) ◽  
pp. 970-973
Author(s):  
Waqas Jehangir ◽  
Alexander D. Karabachev ◽  
Zankhana Mehta ◽  
Mellar Davis

Opioids are an effective treatment for patients with intractable pain. Long-term administration of opioids for pain relief is being delivered by an increasing number of medical providers in the United States including primary care physicians and nonspecialists. One common complication of chronic opioid use is sleep-disordered breathing which can result in various morbidities as well as an increase in all-cause mortality. It is important for providers to understand the relationship between opioids and sleep-disordered breathing as well as methods to improve diagnosis and strategies for treatment. This review aims to update clinicians on the mechanism, diagnosis, and treatment of opioid-related sleep-disordered breathing in order to improve the quality of care for patients with chronic pain.


2015 ◽  
Vol 11 (4) ◽  
pp. 363 ◽  
Author(s):  
Jeffrey DeVido, MD ◽  
Hilary Connery, MD, PhD ◽  
Kevin P. Hill, MD, MHS

Background: Rates of opioid overdose deaths are increasing in the United States, leading to intensified efforts to provide medication-assisted treatments for opioid use disorders. It is not clear what effect opioid agonist treatments (ie, the μ-opioid receptor full agonist methadone and the partial agonist buprenorphine) may have on respiratory function. However, sleep-disordered breathing has been documented in methadone maintenance pharmacotherapy, and there is emerging evidence for similar sleep-disordered breathing in buprenorphine and buprenorphine-naloxone maintenance treatment.Objective: To provide further clinical evidence of sleep-disordered breathing emerging in the context of buprenorphine-naloxone maintenance pharmacotherapy.Methods: The authors report two additional cases of sleep-disordered breathing that developed in patients with severe opioid use disorders, treated successfully as outpatients with buprenorphine-naloxone maintenance. Both patients provided written consent for their clinical information to be included in this case report, and elements of their identities have been masked to provide confidentiality.Results: Two adult female patients, who were stable in buprenorphine-naloxone maintenance treatment developed daytime sleepiness, were referred for evaluation and found to have sleep-disordered breathing. One patient's daytime sleepiness improved with reduction in both buprenorphine-naloxone and other sedating medications as well as initiation of a constant positive airway pressure (CPAP) device. However, the other patient could not tolerate decreases in buprenorphinenaloxone and/or CPAP initiation and her daytime sleepiness persisted.Conclusion: Buprenorphine-naloxone maintenance treatment can be associated with sleep-disordered breathing. It can be difficult to differentiate the cause(s) of sleep-disordered breathing among the effects of buprenorphine-naloxone treatment itself, co-occurring conditions, such as obesity and cigarette smoking or other medications, or some combination thereof. Regardless of etiology, sleep-disordered breathing and its consequences present unique challenges to the patient in recovery from an opioid use disorder and therefore warrants careful evaluation and management.


2017 ◽  
Vol 12 (4) ◽  
pp. 573-586 ◽  
Author(s):  
Susmita Chowdhuri ◽  
Shahrokh Javaheri

Author(s):  
Tetyana Kendzerska ◽  
Tara Gomes ◽  
Atul Malhotra ◽  
Andrea Gershon ◽  
Marcus Povitz ◽  
...  

2020 ◽  
Vol 16 (6) ◽  
pp. 843-845
Author(s):  
Jeremy E. Orr ◽  
Mark S. Wallace ◽  
Atul Malhotra

Sign in / Sign up

Export Citation Format

Share Document